Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex works to build markets for new drugs like Casgevy and Journavx.

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

It is user-friendly and has tiltable LCD with 5.7-inch touch color panel. The LCD monitor ... being used by the customer by obtaining the vertex power difference from the nosepiece aperture ...

After testing the various models in Google's new Gemini 2.0 family, something interesting becomes clear: Google is exploring the potential of specialized AI systems working in concert similar to ...

Enterprises need to tie their generative AI and agentic development efforts to foundational IT principles. AI development ...

Nintendo fans have a theory about the Nintendo Switch 2's black color scheme, suggesting it could mark a turning point for ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

CPI expected to have risen 0.3% on the month. McDonald's investors looking for earnings inflection. Elliott takes BP stake.

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

Moderna Inc . (BMV:MRNA) reported its fourth-quarter earnings for 2024, revealing a significant decline in revenue and a net loss. The company's earnings per share (EPS) were lower than expected, and ...